Evidence map›Paper›PMID 26113648›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2015

High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer.

M P K J Engelen, A M Safar, T Bartter, F Koeman, N E P Deutz

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01172314 (Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01172314 nacompletednot on this map

Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients

TypeinterventionalSponsorTexas A&M UniversityRan2010 to 2012Enrolled41ConditionsNon-small Cell Lung CancerArmsEAA+LEU vs total AA, Total AA vs EAA+LEU
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

M P K J EngelenDepartment of Health and Kinesiology, Center for Translational Research in Aging and Longevity, Texas A&M University, College Station; Department of Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, USA. Electronic address: mpkj.engelen@ctral.org.
A M SafarDepartment of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, USA.
T BartterDepartment of Pulmonary and Critical Care Medicine, University of Arkansas for Medical Sciences, Little Rock, USA.
F KoemanDepartment of Health and Kinesiology, Center for Translational Research in Aging and Longevity, Texas A&M University, College Station; Department of Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, USA.
N E P DeutzDepartment of Health and Kinesiology, Center for Translational Research in Aging and Longevity, Texas A&M University, College Station; Department of Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, USA.
University of Arkansas for Medical Sciences · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR029884 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI LOWERY, CURTIS L · 2009 to 2011
$11.4M
TSQ Vantage Bundle with Acquity UltraPerformance LCS10RR027047 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI DEUTZ, NICOLAAS E · 2010 to 2010
$398k
NCRR NIH HHS S10RR027047NCRR NIH HHS UL1RR029884
6 · The paper itself

Abstract

backgroundConventional nutritional supplements are not or only partly successful in inducing protein accretion in advanced cancer, suggesting an attenuated anabolic response. To prevent muscle wasting and its deleterious consequences, generating an anabolic response is crucial. Dietary essential amino acids (EAA) have anabolic properties in other wasting diseases; however, data in advanced cancer are lacking. PATIENTS AND

methodsIn 13 patients with advanced nonsmall-cell lung cancer (NSCLC) (stage III and IV) and 11 healthy age-matched subjects, we measured protein synthesis and breakdown of the whole body, and net protein anabolism (difference between protein synthesis and breakdown) after intake of 14 g of free EAA with high leucine levels (EAA/leucine) versus a balanced amino acid mixture containing both EAA and non-EAA as present in whey protein, according to a randomized, double-blind, crossover design.

resultsProtein synthesis and net protein anabolism were higher after intake of the EAA/leucine than the balanced amino acid mixture (P < 0.001), independent of presence of cancer. A highly significant linear relationship between net protein anabolism and the amount of EAA available in the systemic circulation (R(2): 0.85, P < 0.001) was found in both groups. The presence of muscle or recent weight loss, systemic inflammatory response, or length of survival did not influence this relationship. High leucine levels in the EAA/leucine mixture was of no anabolic benefit.

conclusionsThere is no anabolic resistance or attenuated anabolic potential to intake of 14 g of EAA/leucine or balanced amino acid mixture in advanced (mainly stage III) NSCLC. The high anabolic potential of dietary EAA in cancer patients is independent of their nutritional status, systemic inflammatory response or disease trajectory, suggesting a key role of EAA in new nutritional approaches to prevent muscle loss, thereby improving outcome of patients with advanced cancer. CLINICALTRAILSGOV: NCT01172314.

Indexed as

Dietary SupplementsAgedAmino Acids, EssentialAnabolic AgentsCachexiaCarcinoma, Non-Small-Cell LungDouble-Blind MethodHumansLung NeoplasmsMaleMiddle AgedMuscle, SkeletalMuscular AtrophyProtein BiosynthesisProteolysisWhey ProteinsAmino Acids, EssentialAnabolic AgentsWhey Proteinscachexiadietary essential amino acidsnonsmall-cell lung cancerprotein anabolismstable isotopestranslational research

Identifiers

PMID26113648
PMCPMC4551158
OpenAlexW2292694384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.